compound 7i

Compound 7i is an experimental **amide-enriched 2-(1H)-quinazolinone** small molecule reported in a 2024 medicinal chemistry publication as part of a 7a-j series evaluated for anticancer activity. In cell-based MTT assays, it showed strong apoptotic and cytotoxic activity, particularly against the **MCF7 breast cancer** cell line, and the authors supported its anticancer hypothesis with **in silico docking to the epidermal growth factor receptor tyrosine kinase domain** together with DFT, molecular dynamics, and ADME analyses. It appears to be an early preclinical research compound rather than a clinically developed drug, with no identified commercial developer, brand name, approved formulation, or human clinical development record in the provided evidence.

Other names

amide-enriched 2-(1H)-quinazolinone derivative 7iquinazolinone derivative 7i